myosin heavy chain 13Genealiases: MyHC-IIL · MyHC-eo
Q-omics provides the consensus-scored MYH13 profile across patient tissues and cancer cell-line models. MYH13 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MYH13 is differentially expressed in 10, with the highest sampling consensus in BRCA. Additionally, MYH13 protein abundance shows 27,853 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, BRCA, and LUAD as cancer lineages where MYH13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYH13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYH13 survival associations across molecular data types. MYH13 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (12) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYH13 RNA expression–survival associations across cancer types. High MYH13 expression shows unfavorable associations in ACC, KIRC, PCPG, BLCA and GBM, but favorable associations in CHOL. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MYH13 RNA expression.
This table summarizes MYH13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in BRCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for MYH13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYH13 shows lower tumor expression in HNSC and ESCA and higher tumor expression in BRCA, KIRC, LIHC and PRAD. The BRCA box plot shows higher MYH13 RNA expression in tumor versus normal tissue (log2 FC = +0.218, t-test p < 0.001).
This table shows molecular features associated with MYH13 in patient tissues and cancer cell lines. In patient samples, MYH13 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MYH13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
